Asthma/COPD:
Indications for: INCRUSE ELLIPTA
Maintenance treatment of COPD.
Adult Dosage:
Take at same time every day. 1 inhalation every 24hrs.
Children Dosage:
Not established.
INCRUSE ELLIPTA Contraindications:
Severe hypersensitivity to milk proteins.
INCRUSE ELLIPTA Warnings/Precautions:
Not indicated for relief of acute bronchospasm. Do not initiate in rapidly or acutely deteriorating COPD. Do not exceed recommended dose. Reevaluate periodically. Prescribe a short-acting, inhaled β2-agonist for acute symptoms; monitor for increased need. Discontinue if paradoxical bronchospasm (use alternatives) or hypersensitivity reactions occur. Narrow-angle glaucoma. Urinary retention. Prostatic hyperplasia. Bladder-neck obstruction. Severe hepatic impairment. Pregnancy. Nursing mothers.
INCRUSE ELLIPTA Classification:
Anticholinergic.
INCRUSE ELLIPTA Interactions:
Additive effects with concomitant other anticholinergic-containing drugs; avoid.
Adverse Reactions:
Nasopharyngitis, URTI, cough, arthralgia; visual disturbances, paradoxical bronchospasm.
Generic Drug Availability:
NO
How Supplied:
Dry pwd inhaler—30 doses
